



香港大學 - 巴斯德研究中心
HKU-Pasteur Research Pole

Seminar

“Disruptive technologies enabling patient based drug discovery”

by

Ulf NEHRBASS, PhD

Ksilink

Chief Executive Officer

Biosketch

Ulf Nehrbass serves as CEO of KSILINK, the new French German Advanced Translational Center. In creating this new center he is bringing on board his experience in translational drug discovery, utilizing a combination of disruptive technologies able to accelerate discovery programs and produce higher success rates. Dr Nehrbass has spent his recent career at Institut Pasteur in Paris and in its international network. As the Director and founder of Institut Pasteur Korea he has been invested in the application of basic research towards therapy development. There he gathered an international team to establish one of the first translational drug discovery institutes. The project, starting in 2004, was innovative as it relied on target free, visual drug discovery with live disease models. Amongst others, this has resulted in the development of Q203, a first in class compound and the world's most potent candidate against mdr and xdr TB. Dr Nehrbass is also founder and former CEO of Qurient Therapeutics, a successful Biotech in Seoul, Korea, nominated Korea's most attractive Biotech Investment Asset in 2010, which raised over €300M in its 2016 I.P.O. Prior to that he has worked in life science research, as a Chef d'Unite at the Institut Pasteur in Paris and a research associate with the Howard Hughes Medical Institute at the Rockefeller University in New York. He did his studies in Biochemistry at Cambridge University, UK and performed his thesis work with PhD fellowship EMBL in Heidelberg. In 2006 Ulf Nehrbass was nominated EMBO fellow.

Date: Monday, 3rd July 2017

Time: 11:30 am

Venue: Seminar Room 7 (HRI-S7), 7th Floor
HKJC Building for Interdisciplinary Research
5 Sassoon Road, Pokfulam, Hong Kong

ALL ARE WELCOME